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In this issue of Biophysical Journal,
Gregory et al. present a new model for
the action of cecropin A on synthetic
lipid vesicles (1). Cecropin A was one
of the first polypeptide antibiotics iden-
tified by Boman and co-workers (2)
following his observation that anti-
microbial activity could be induced in
insects by bacterial infection (3). Since
then, many other ribosomally synthe-
sized antibiotics have been identified in
both plants and animals, where it has
become clear that they are important in
diverse ways to host defense. When
expressed in transgenic animals, for
example, they can enhance host de-
fenses against bacterial infection (4).
Human deficiency states, on the other
hand, lead to an increased incidence of
infection (5,6) and inflammatory bowel
disease (7).
Despite thousands of articles about
hundreds of these polypeptide anti-
biotics over several decades, basic ques-
tions about their mechanism of action
remain unanswered. Most investigators
have concluded that they act solely by
permeabilizing the bacterial cell mem-
brane. Although strong evidence for
another mechanism of action has not
yet emerged, this conclusion may not
represent the whole story because poly-
peptide antibiotics clearly have other
significant effects on bacteria (8–11).
Moreover, few naturally occurring an-
tibiotics have only one mechanism of
action, presumably because antibiotics
with multiple mechanisms of action
have been selected to overcome the
development of resistance to any one
mechanism. Resistance to polypeptide
antibiotics is common, and different
polypeptides tend to have different pat-
terns of resistance or susceptibility among
bacteria. Resistance to any one poly-
peptide often varies widely among
closely related bacterial species, and
can even vary among different strains
of the same species.
It is difficult to explain these diverse
patterns of resistance with a single
mechanism of action targeting lipids in
the bacterial cell membrane. Of course,
resistance may occur when access to the
site of action is blocked. This explana-
tion may account for the resistance
observed in one case where changes in
growth medium induced changes in the
outer membrane (i.e., not the cell mem-
brane) of a Gram-negative bacterium
(12). However, if polypeptide antibi-
otics must overcome selective barriers
to reach their site of action, any de-
scription of their mechanism of action
must be expanded to include this capa-
bility.
In any case, bacteria do not develop
secondary resistance when cultivated in
subinhibitory concentrations of poly-
peptide antibiotics, as is usually the
case with antibiotics in other classes.
This ‘‘resistance to acquired resistance’’
has drawn considerable attention among
investigators seeking new antibiotics
for use against the growing menace of
pathogens with multidrug resistance.
Moreover, most animals produce an
assortment of polypeptide antibiotics.
These factors may have allowed poly-
peptide antibiotics to flourish in nature
despite having only a single mechanism
of action.
Given the complex and fundamental
questions that persist about their mech-
anism of action in bacteria, one must be
circumspect when drawing conclusions
about polypeptide antibiotics from
studies of their effects on synthetic
lipid vesicles. Vesicles do not have the
complex composition or structure of
bacterial membranes, and it isn’t clear
whether they more closely resemble the
membranes of bacteria that are suscep-
tible or resistant to a particular poly-
peptide antibiotic. Yet because of their
simplicity, synthetic vesicles facilitate
quantitatively rigorous investigations
into the interactions of polypeptides
with membranes.
The model of Gregory et al. is based
solely on the interactions of cecropin
A with synthetic lipid vesicles, but it
is nonetheless impressive in several
respects. First, and most notably, the
model is quantitatively elegant. It ac-
counts for the kinetics of vesicle con-
tents release with a single adjustable
parameter, b. Second, this parameter
has a clear physical interpretation,
being the ratio of the rates of formation
and relaxation of a ‘‘pore state.’’ Third,
the model provides key insights into
mechanism of action while discrimi-
nating against alternative models.
The mechanism of action suggested
by the model of Gregory et al. is that
polypeptides antibiotics induce the tran-
sient existence of a chaotic pore state by
creating structural distortions and ten-
sionswhen they situate in a lipid bilayer.
Carefully measured on- and off-rates
appear to exclude earlier versions of
this mechanism involving polypeptide
translocation across lipid bilayers (13,
14). They also weigh against the toroi-
dal pore model, and there is no need for
an organized structure of this type in
Gregory’s model. The relatively sparse
surface coverage needed to create the
pore state, and the restoration of poly-
peptide binding kinetics after relaxation
of the pore state, both weigh against the
popular carpet model.
The nascent model of Gregory et al.
is now obliged to run a gauntlet of
challenges. First among these chal-
lenges is a demonstration that it applies
to polypeptides other than cecropin A.
Information about b for a series of
antibiotics may provide insight into the
features of polypeptide sequences that
account for their antibiotic activity.
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Additional important challenges in-
clude a demonstration that the effects
of polypeptide antibiotics on vesicles
faithfully represent what happens on
bacterial membranes, and an expla-
nation for their differential activity
against prokaryotic versus eukaryotic
membranes.
It is commonly assumed that cationic
polypeptide antibiotics like cecropin A
act against bacteria and not eukaryotic
cells because bacteria have anionic
lipids on the outer surface of their cell
membranes. However, there is little
experimental support for this assump-
tion. Gram-negative bacteria have more
protein than lipid in their cell mem-
branes, anionic lipids are a minority
component among the lipids that are
present (15), and we do not know
how they are distributed between the
inner and outer surfaces of the cell
membrane—there is simply no data. A
much higher fraction of lipid in Gram-
positive bacteria is anionic, but these
bacteria are not more susceptible to
polypeptide antibiotics. Gregory et al.
observed that anionic lipids have rela-
tively little effect on b, suggesting that
they are not directly involved in mem-
brane permeabilization (16). On the
other hand, anionic lipids did influence
the amount of polypeptide bound to the
vesicles. If this effect is due to nonspe-
cific electrostatic interactions, then
other more abundant anions (e.g., poly-
saccharides or membrane proteins)
may have a greater role than anionic
lipids in binding and concentrating
polypeptide antibiotics on the bacterial
surface.
Whether or not Gregory’s model
survives the challenges it now faces,
one may hope that its initial success
stimulates further quantitative investi-
gation into a host defense mechanism
that is so broadly applied in nature.
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